000963 华东医药
交易中 07-11 13:51:45
资讯
新帖
简况
华东医药:子公司获注射用HDM2020临床试验批准
格隆汇 · 06-26
华东医药:子公司获注射用HDM2020临床试验批准
华东医药三大GLP-1创新药亮相ADA大会
市场资讯 · 06-22
华东医药三大GLP-1创新药亮相ADA大会
华东医药:未来如有确定的自研产品对外合作进展公司将及时公告
证券之星 · 06-20
华东医药:未来如有确定的自研产品对外合作进展公司将及时公告
华东医药:公立医院完善医疗美容科室为公司医美产品提供更广阔应用场景
证券之星 · 06-20
华东医药:公立医院完善医疗美容科室为公司医美产品提供更广阔应用场景
华东医药:公司HDM1002体重管理适应症的1b期临床数据将于近期在ADA大会公布
证券之星 · 06-20
华东医药:公司HDM1002体重管理适应症的1b期临床数据将于近期在ADA大会公布
华东医药:公司创新药研发聚焦内分泌、自身免疫和肿瘤三大治疗领域
证券之星 · 06-16
华东医药:公司创新药研发聚焦内分泌、自身免疫和肿瘤三大治疗领域
东方妍美赴港上市 押注童颜针四年估值涨近七倍【IPO观察】
投资者网 · 06-15
东方妍美赴港上市 押注童颜针四年估值涨近七倍【IPO观察】
华东医药最新公告:全资子公司获得0.3%罗氟司特泡沫临床试验批准通知书
证券之星 · 06-10
华东医药最新公告:全资子公司获得0.3%罗氟司特泡沫临床试验批准通知书
东吴证券:给予华东医药买入评级
证券之星 · 06-09
东吴证券:给予华东医药买入评级
华东医药(000963.SZ):中美华东申报的HDM1010片药品临床试验申请获美国FDA批准
智通财经 · 06-09
华东医药(000963.SZ):中美华东申报的HDM1010片药品临床试验申请获美国FDA批准
开源证券:给予华东医药买入评级
证券之星 · 06-02
开源证券:给予华东医药买入评级
华东医药最新公告:全资子公司收到雷珠单抗注射液上市许可申请受理通知书
证券之星 · 06-02
华东医药最新公告:全资子公司收到雷珠单抗注射液上市许可申请受理通知书
中证全指医药卫生行业指数上涨0.36%,前十大权重包含华东医药等
金融界 · 05-30
中证全指医药卫生行业指数上涨0.36%,前十大权重包含华东医药等
华东医药:公司DR30206是一种靶向PD-L1、VEGF和TGF-β 的抗体融合蛋白
证券之星 · 05-22
华东医药:公司DR30206是一种靶向PD-L1、VEGF和TGF-β 的抗体融合蛋白
华东医药:发酵虫草菌粉专利侵权诉讼已完成浙江省高级人民法院一审两次开庭
金融界 · 05-22
华东医药:发酵虫草菌粉专利侵权诉讼已完成浙江省高级人民法院一审两次开庭
华东医药:针对发酵虫草菌粉的专利侵权诉讼已完成一审两次开庭
证券之星 · 05-22
华东医药:针对发酵虫草菌粉的专利侵权诉讼已完成一审两次开庭
群益证券:给予华东医药增持评级,目标价47.8元
证券之星 · 05-09
群益证券:给予华东医药增持评级,目标价47.8元
华东医药:公司2024年年度报告电子版已于2025年4月18日通过指定信息披露平台巨潮资讯网披露
证券之星 · 05-07
华东医药:公司2024年年度报告电子版已于2025年4月18日通过指定信息披露平台巨潮资讯网披露
华东医药(000963.SZ):注射用HDM2005临床试验申请获得批准
智通财经网 · 05-06
华东医药(000963.SZ):注射用HDM2005临床试验申请获得批准
恒瑞医药、华东医药等多家药企,一季度研发投入大增
动脉网 · 05-05
恒瑞医药、华东医药等多家药企,一季度研发投入大增
加载更多
公司概况
公司名称:
华东医药股份有限公司
所属行业:
零售业
上市日期:
2000-01-27
主营业务:
华东医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是商业、制造业、医美业务。公司是膺E药经理人“2024中国医药上市公司竞争力20强”“2024中国医药创新企业100强”。
发行价格:
5.76
{"stockData":{"symbol":"000963","market":"SZ","secType":"STK","nameCN":"华东医药","latestPrice":40.05,"timestamp":1752213105000,"preClose":39.84,"halted":0,"volume":8201280,"delay":0,"changeRate":0.0053,"floatShares":1752000000,"shares":1754000000,"eps":2.0321,"marketStatus":"交易中","change":0.21,"latestTime":"07-11 13:51:45","open":39.84,"high":40.45,"low":39.73,"amount":329000000,"amplitude":0.0181,"askPrice":40.06,"askSize":24,"bidPrice":40.04,"bidSize":19,"shortable":0,"etf":0,"ttmEps":2.0321,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1752217200000},"marketStatusCode":2,"adr":0,"adjPreClose":39.84,"symbolType":"stock","openAndCloseTimeList":[[1752197400000,1752204600000],[1752210000000,1752217200000]],"highLimit":43.82,"lowLimit":35.86,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1754077048,"isCdr":false,"pbRate":2.9,"roa":"--","peRate":19.708676,"roe":"3.88%","epsLYR":2.0046,"committee":0.746141,"marketValue":70251000000,"turnoverRate":0.0047,"status":0,"floatMarketCap":70165000000},"requestUrl":"/m/hq/s/000963","defaultTab":"news","newsList":[{"id":"2546789933","title":"华东医药:子公司获注射用HDM2020临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2546789933","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546789933?lang=zh_cn&edition=full","pubTime":"2025-06-26 18:13","pubTimestamp":1750932825,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0175","BK0188","LU2328871848.SGD","BK1209","BK0183","03347","BK1576","BK1583","000963","06078","BK0196","BK0132","LU1969619763.USD","LU0329678337.USD","LU0737861772.HKD","LU2488822045.USD","BK0187","LU0329678170.USD","BK1141","BK0209"],"gpt_icon":0},{"id":"2545455070","title":"华东医药三大GLP-1创新药亮相ADA大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2545455070","media":"市场资讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545455070?lang=zh_cn&edition=full","pubTime":"2025-06-23 05:41","pubTimestamp":1750628460,"startTime":"0","endTime":"0","summary":"6月22日晚,华东医药传出好消息,公司三大GLP-1创新药物的研究成果在2025年第85届美国糖尿病协会科学会议上重磅亮相。此次亮相ADA大会的HDM1005注射液,是一项随机、双盲、安慰剂对照、单次和多次给药剂量递增的I期研究。不良事件与同类药物一致。两组安全性良好,HDG1901组TEAE、TRAE和SAE的发生率数值上均低于诺和泰组。华东医药入围并以第41位的排名实现突破,标志着其综合竞争力获国际认可。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/t/2025-06-23/doc-infayyts1009767.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK0209","BK0175","BK0196","BK1574","BK4590","LU1969619763.USD","BK4144","LU2328871848.SGD","000963","BK0187","06978","BK0183","BK0188","GLP","159992","BK0132"],"gpt_icon":0},{"id":"2544927142","title":"华东医药:未来如有确定的自研产品对外合作进展公司将及时公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2544927142","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544927142?lang=zh_cn&edition=full","pubTime":"2025-06-20 17:00","pubTimestamp":1750410049,"startTime":"0","endTime":"0","summary":"证券之星消息,华东医药(000963)06月20日在投资者关系平台上答复投资者关心的问题。投资者提问:请问在2024年度大会中提到已经在洽谈的bd交易目前是否有进展,涉及到金额? 预计能否在2025年完成交易? 以及是否考虑在半年报中公开披露各个商业占比,比如医美占比以及创新药各个销售情况? 创新药竞争激烈,进度决定一切,希望公司能把握机会。华东医药回复:您好!未来如有确定的自研产品对外合作进展,公司将按照信息披露相关规定及时公告。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062000024829.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","BK0132","BK0188","BK0187","BK0209","LU2328871848.SGD","000963","BK0183","BK0175","BK0196"],"gpt_icon":0},{"id":"2544426331","title":"华东医药:公立医院完善医疗美容科室为公司医美产品提供更广阔应用场景","url":"https://stock-news.laohu8.com/highlight/detail?id=2544426331","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544426331?lang=zh_cn&edition=full","pubTime":"2025-06-20 17:00","pubTimestamp":1750410049,"startTime":"0","endTime":"0","summary":"证券之星消息,华东医药06月20日在投资者关系平台上答复投资者关心的问题。谢谢华东医药回复:您好!公立医院逐步完善医疗美容科室建设、提升规范化服务能力,与医美行业“回归医疗本质”的趋势高度契合,这为公司具有合规优势及高品质的医美产品提供了更广阔的应用场景。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062000024827.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","LU1969619763.USD","BK0196","BK0209","000963","LU2328871848.SGD","BK0188","BK0183","BK0175","BK0187"],"gpt_icon":0},{"id":"2544714417","title":"华东医药:公司HDM1002体重管理适应症的1b期临床数据将于近期在ADA大会公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2544714417","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544714417?lang=zh_cn&edition=full","pubTime":"2025-06-20 16:57","pubTimestamp":1750409842,"startTime":"0","endTime":"0","summary":"证券之星消息,华东医药(000963)06月20日在投资者关系平台上答复投资者关心的问题。投资者提问:你好,董秘,请问HDM1002的减肥二期临床数据会在这周的ADA大会期间公布吗华东医药回复:您好!公司HDM1002体重管理适应症的1b期临床数据将于近期在ADA大会公布。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062000024709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","BK0209","BK0196","BK0188","LU2328871848.SGD","BK0183","000963","BK0187","BK0175","BK0132"],"gpt_icon":0},{"id":"2543462913","title":"华东医药:公司创新药研发聚焦内分泌、自身免疫和肿瘤三大治疗领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2543462913","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543462913?lang=zh_cn&edition=full","pubTime":"2025-06-16 16:24","pubTimestamp":1750062280,"startTime":"0","endTime":"0","summary":"证券之星消息,华东医药06月16日在投资者关系平台上答复投资者关心的问题。海外大厂靠百亿大技术壁垒的大单品支撑万亿市值的华东医药回复:您好!公司创新药研发聚焦内分泌、自身免疫和肿瘤三大治疗领域,以具有“临床价值、药物经济学价值、商业价值”为出发点,既注重核心产品打造,也注重潜力品种的培养和产品管线的持续丰富。公司医美业务多元化布局旨在覆盖差异化需求,致力于成为全球领先的医美综合解决方案提供商。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061600019274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","BK0183","BK0196","LU2328871848.SGD","159992","06978","BK0175","000963","BK0132","BK0188","BK0209","BK1574","BK1161","BK0187"],"gpt_icon":0},{"id":"2543695888","title":"东方妍美赴港上市 押注童颜针四年估值涨近七倍【IPO观察】","url":"https://stock-news.laohu8.com/highlight/detail?id=2543695888","media":"投资者网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543695888?lang=zh_cn&edition=full","pubTime":"2025-06-15 08:01","pubTimestamp":1749945716,"startTime":"0","endTime":"0","summary":"四年估值上涨近七倍据招股书披露。2023年,东方妍美成立,并全资控股了江苏西宏。若从江苏西宏的天使轮算起,到东方妍美递表前的最后两轮融资,四年时间,东方妍美的估上涨了近七倍。叠加行政开支,导致东方妍美连续亏损。多家公司角逐“童颜针”东方妍美要扭转亏损局势,只有等待核心产品XH301上市。截至2024年末,东方妍美账上的现金及现金等价物只有3319.7万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/15080151078687.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1969619763.USD","BK0114","000999","BK0196","BK1191","IE00B1BXHZ80.USD","BK0010","LU0882574139.USD","BK0042","IE00BYV24P56.USD","LU2328871848.SGD","CMC","BK0188","IE00BKVL7J92.USD","IE00BHPRN162.USD","LU0170899867.USD","603127","BK0175","BK0187","BK0201","688621","IE00BVYPNQ40.USD","BK0012","600200","LU2488822045.USD","SG9999004220.SGD","IE00BVYPNP33.GBP","IE00BGHQDM52.EUR","00867","BK0113","BK0132","LU0267386448.USD","300003","IE00BZ1G4Q59.USD","300896","SG9999015986.USD","BK0185","BK0209","BK0251","BK0216","BK0183","LU0149725797.USD","LU0971096721.USD","000963","BK4006","BK0028","BK0239","SG9999015978.USD","BK1593","LU1363072403.SGD"],"gpt_icon":0},{"id":"2542311114","title":"华东医药最新公告:全资子公司获得0.3%罗氟司特泡沫临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2542311114","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542311114?lang=zh_cn&edition=full","pubTime":"2025-06-10 20:01","pubTimestamp":1749556881,"startTime":"0","endTime":"0","summary":"华东医药(000963.SZ)公告称,公司全资子公司中美华东收到NMPA核准签发的《药物临床试验批准通知书》,同意0.3%罗氟司特泡沫在脂溢性皮炎患者中开展有效性和安全性的多中心、随机、双盲、赋形剂平行对照的III期临床试验。该药物是FDA二十多年来首个批准的具有新作用机制的脂溢性皮炎外用药物,有望为脂溢性皮炎患者带来新的治疗选择。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061000032884.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0183","LU1969619763.USD","BK0209","BK1141","BK0175","BK0187","BK0188","000963","BK1583","LU2328871848.SGD","03347","BK0132","BK1576"],"gpt_icon":0},{"id":"2542039355","title":"东吴证券:给予华东医药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2542039355","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542039355?lang=zh_cn&edition=full","pubTime":"2025-06-10 07:40","pubTimestamp":1749512429,"startTime":"0","endTime":"0","summary":"东吴证券股份有限公司朱国广,冉胜男,苏丰近期对华东医药进行研究并发布了研究报告《白马药企转型创新,开启发展新阶段》,给予华东医药买入评级。考虑到公司未来创新药品种陆续上市贡献业绩,及创新能力兑现带来估值重塑,维持“买入”评级。最新盈利预测明细如下:该股最近90天内共有18家机构给出评级,买入评级17家,增持评级1家;过去90天内机构目标均价为48.58。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061000004332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000963","601555"],"gpt_icon":0},{"id":"2542047978","title":"华东医药(000963.SZ):中美华东申报的HDM1010片药品临床试验申请获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2542047978","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542047978?lang=zh_cn&edition=full","pubTime":"2025-06-09 17:04","pubTimestamp":1749459843,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华东医药 发布公告,2025年6月6日,公司全资子公司杭州中美华东制药有限公司收到美国食品药品监督管理局通知,由中美华东申报的HDM1010片药品临床试验申请已获得美国FDA批准,可在美国开展I期临床试验,适应症为2型糖尿病。据悉,HDM1010片是由中美华东自主研发的HDM1002/SGLT2抑制剂固定剂量复方制剂。其中HDM1002是由中美华东自主研发并拥有全球知识产权的创新型小分子药物,是具有口服活性、强效、高选择性的GLP-1受体小分子完全激动剂。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1302930.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK1583","BK1576","LU2328871848.SGD","000963","BK0175","03347","LU1969619763.USD","BK0132","BK0183","BK0188","BK0209","BK0187","BK1141"],"gpt_icon":0},{"id":"2540719780","title":"开源证券:给予华东医药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2540719780","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540719780?lang=zh_cn&edition=full","pubTime":"2025-06-03 07:25","pubTimestamp":1748906722,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,余克清,刘艺近期对华东医药进行研究并发布了研究报告《公司深度报告:创新转型再出发,多产品步入收获期》,给予华东医药买入评级。最新盈利预测明细如下:该股最近90天内共有17家机构给出评级,买入评级16家,增持评级1家;过去90天内机构目标均价为49.22。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060300004195.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","000963"],"gpt_icon":0},{"id":"2540763258","title":"华东医药最新公告:全资子公司收到雷珠单抗注射液上市许可申请受理通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2540763258","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540763258?lang=zh_cn&edition=full","pubTime":"2025-06-02 15:50","pubTimestamp":1748850625,"startTime":"0","endTime":"0","summary":"华东医药(000963.SZ)公告称,全资子公司中美华东收到国家药品监督管理局签发的《受理通知书》,雷珠单抗注射液(研发代码:HJY28)上市许可申请获得受理。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060200001522.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","BK0188","LU2328871848.SGD","BK0209","000963","BK0196","BK0183","BK0175","BK0187","BK0132"],"gpt_icon":0},{"id":"2539728227","title":"中证全指医药卫生行业指数上涨0.36%,前十大权重包含华东医药等","url":"https://stock-news.laohu8.com/highlight/detail?id=2539728227","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539728227?lang=zh_cn&edition=full","pubTime":"2025-05-30 21:09","pubTimestamp":1748610588,"startTime":"0","endTime":"0","summary":"数据统计显示,中证全指医药卫生行业指数近一个月上涨6.05%,近三个月上涨4.60%,年至今上涨5.36%。从中证全指医药卫生行业指数持仓样本的行业来看,医药卫生占比100.00%。在样本公司有特殊事件发生,导致其行业归属发生变更时,将对中证全指行业指数样本进行相应调整。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/05/30210950784776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0132","LU1969619763.USD","BK0196","BK0209","000963","000985.SH","LU2328871848.SGD","BK0188","BK0183","BK0175","BK0187"],"gpt_icon":0},{"id":"2537965837","title":"华东医药:公司DR30206是一种靶向PD-L1、VEGF和TGF-β 的抗体融合蛋白","url":"https://stock-news.laohu8.com/highlight/detail?id=2537965837","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537965837?lang=zh_cn&edition=full","pubTime":"2025-05-22 08:55","pubTimestamp":1747875317,"startTime":"0","endTime":"0","summary":"投资者提问:你好,董秘,近两年康方生物和三生制药的PD-1/VEGF的双靶药物都相继被大额授权给了海外公司,公司的DR30206靶向PD-L1、VEGF和TGF-β ,相比PD-1/VEGF药物有什么优势吗,目前临床效果怎么样,另外该药物有对外授权的机会吗华东医药回复:您好!公司DR30206是一种靶向PD-L1、VEGF和TGF-β 的抗体融合蛋白,通过阻断PD-1/PD-L1信号通路,恢复耗竭性CD8+T细胞的增殖;通过特异性结合游离VEGF和TGF-β,减少肿瘤新生血管的形成同时解除免疫抑制,从而达到治疗肿瘤的目的。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052200005160.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0196","BK0209","BK0188","LU1969619763.USD","BK0175","000963","BK0183","BK0187","LU2328871848.SGD"],"gpt_icon":0},{"id":"2537963092","title":"华东医药:发酵虫草菌粉专利侵权诉讼已完成浙江省高级人民法院一审两次开庭","url":"https://stock-news.laohu8.com/highlight/detail?id=2537963092","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537963092?lang=zh_cn&edition=full","pubTime":"2025-05-22 08:49","pubTimestamp":1747874969,"startTime":"0","endTime":"0","summary":"金融界5月22日消息,有投资者在互动平台向华东医药提问:你好,领导!请问贵公司告佐力药业侵权一案到底有没有结果?????已经一年多了,烂尾了吗?请详细告诉投资者,有点虎头蛇尾,麻烦对投资者负责下!公司回答表示:您好!截止目前,公司针对发酵虫草菌粉的专利侵权诉讼,已完成浙江省高级人民法院一审两次开庭,一审尚未有结果。感谢您的关注!\n\n\r\n 责任编辑:栎树","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/05/22084950580117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["000963","BK0132","BK0188","LU2328871848.SGD","BK0209","BK0187","BK0196","BK0183","LU1969619763.USD","BK0175"],"gpt_icon":0},{"id":"2537696325","title":"华东医药:针对发酵虫草菌粉的专利侵权诉讼已完成一审两次开庭","url":"https://stock-news.laohu8.com/highlight/detail?id=2537696325","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537696325?lang=zh_cn&edition=full","pubTime":"2025-05-22 08:48","pubTimestamp":1747874900,"startTime":"0","endTime":"0","summary":"证券之星消息,华东医药(000963)05月21日在投资者关系平台上答复投资者关心的问题。投资者提问:你好,领导!请问贵公司告佐力药业侵权一案到底有没有结果?????已经一年多了,烂尾了吗?请详细告诉投资者,有点虎头蛇尾,麻烦对投资者负责下!华东医药回复:您好!截止目前,公司针对发酵虫草菌粉的专利侵权诉讼,已完成浙江省高级人民法院一审两次开庭,一审尚未有结果。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052200005092.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0132","LU1969619763.USD","LU2328871848.SGD","BK0209","BK0188","BK0196","BK0183","BK0175","000963"],"gpt_icon":0},{"id":"2534512619","title":"群益证券:给予华东医药增持评级,目标价47.8元","url":"https://stock-news.laohu8.com/highlight/detail?id=2534512619","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534512619?lang=zh_cn&edition=full","pubTime":"2025-05-09 15:05","pubTimestamp":1746774331,"startTime":"0","endTime":"0","summary":"群益证券(香港)有限公司王睿哲近期对华东医药进行研究并发布了研究报告《25Q1扣非净利YOY+17%,符合预期》,给予华东医药增持评级,目标价47.8元。 风险提示:新药研发进度及销售不及预期,医美销售不及预期,汇兑损益风险最新盈利预测明细如下:该股最近90天内共有18家机构给出评级,买入评级17家,增持评级1家;过去90天内机构目标均价为46.59。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050900017432.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000963","161027"],"gpt_icon":0},{"id":"2533737916","title":"华东医药:公司2024年年度报告电子版已于2025年4月18日通过指定信息披露平台巨潮资讯网披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2533737916","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533737916?lang=zh_cn&edition=full","pubTime":"2025-05-07 16:12","pubTimestamp":1746605546,"startTime":"0","endTime":"0","summary":"证券之星消息,华东医药05月07日在投资者关系平台上答复投资者关心的问题。能不能给我寄一份24年公司年报?公司2024年年度报告电子版已于2025年4月18日通过指定信息披露平台巨潮资讯网披露。目前纸质版年报尚在印刷过程中,因印量有限,在优先满足预约股东需要的前提下,公司将会尽量满足其他投资者需要。您可通过公司投资者关系邮箱或拨打投资者热线提交您的邮寄信息,我们将尽量安排寄送。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050700023081.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","000963","BK0196","BK0132","BK0209","LU2328871848.SGD","BK0183","BK0188","LU1969619763.USD","BK0187"],"gpt_icon":0},{"id":"2533506338","title":"华东医药(000963.SZ):注射用HDM2005临床试验申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2533506338","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533506338?lang=zh_cn&edition=full","pubTime":"2025-05-06 17:21","pubTimestamp":1746523260,"startTime":"0","endTime":"0","summary":"华东医药发布公告,2025年5月6日,公司全资子公司杭州中美华东制药有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,由中美华东申报的注射用HDM2005临床试验申请获得批准。注射用HDM2005在中国和美国的临床试验于2024年6月分别获得NMPA和美国食品药品监督管理局批准,适应症为晚期恶性肿瘤。2025年2月,HDM2005的套细胞淋巴瘤适应症获得美国FDA孤儿药资格认定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-05-06/doc-inevrkux0607733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","03347","BK0132","BK0188","LU2328871848.SGD","BK0183","BK0196","000963","LU1969619763.USD","BK0209","BK1141","BK0187","BK0175","BK1576"],"gpt_icon":0},{"id":"2533322008","title":"恒瑞医药、华东医药等多家药企,一季度研发投入大增","url":"https://stock-news.laohu8.com/highlight/detail?id=2533322008","media":"动脉网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533322008?lang=zh_cn&edition=full","pubTime":"2025-05-05 08:22","pubTimestamp":1746404520,"startTime":"0","endTime":"0","summary":"恒瑞医药和华东医药在2025年一季度的研发投入显著增加。恒瑞医药一季度营收72.06亿元,同比增长20.14%;净利18.74亿元,同比增长36.90%;研发费用高达15.33亿元。未来三年,恒瑞预计获批上市47项创新成果,涵盖多个疾病领域。华东医药一季度实现营业收入107.36亿元,增长3.12%;净利润9.15亿元,增长6.06%;研发费用增长82.99%至5.15亿元,显示公司在创新药、医疗器械和生物类似药领域的大力投入。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050508421394ec8205&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050508421394ec8205&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["000963","BK0183","LU1064131003.USD","LU2148510915.USD","LU0405327494.USD","BK0239","600276","LU1064130708.USD","LU2328871848.SGD","BK0188","01276","LU1969619763.USD","BK0209","BK0028","BK0060","BK0132","LU1328615791.USD","BK0187","BK0175","LU0405327148.USD","LU2488822045.USD","BK0012","BK0196"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1752213108170,"stockEarnings":[{"period":"1week","weight":-0.0129},{"period":"1month","weight":-0.0892},{"period":"3month","weight":0.091},{"period":"6month","weight":0.2371},{"period":"1year","weight":0.5296},{"period":"ytd","weight":0.1667}],"compareEarnings":[{"period":"1week","weight":0.014},{"period":"1month","weight":0.0369},{"period":"3month","weight":0.0838},{"period":"6month","weight":0.1077},{"period":"1year","weight":0.194},{"period":"ytd","weight":0.0471}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华东医药股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"75847人(较上一季度减少9.04%)","perCapita":"23098股","listingDate":"2000-01-27","address":"浙江省杭州市拱墅区中山北路439号4、7楼","registeredCapital":"175407万元","survey":" 华东医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是商业、制造业、医美业务。公司是膺E药经理人“2024中国医药上市公司竞争力20强”“2024中国医药创新企业100强”。","listedPrice":5.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华东医药(000963)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华东医药(000963)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华东医药,000963,华东医药股票,华东医药股票老虎,华东医药股票老虎国际,华东医药行情,华东医药股票行情,华东医药股价,华东医药股市,华东医药股票价格,华东医药股票交易,华东医药股票购买,华东医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华东医药(000963)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华东医药(000963)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}